Anti-BDCA2 Antibody Formulations for Subcutaneous Immune Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for BDCA2-associated disorders such as systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), and discoid lupus erythematosus (DLE) are inadequate in effectively targeting the underlying immune dysfunction.
Innovation Solution
The development of pharmaceutical compositions comprising an anti-BDCA2 antibody or BDCA2-binding fragments, along with sucrose and arginine hydrochloride, to create a formulation optimized for subcutaneous administration, with specific concentrations and pH levels designed to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for BDCA2-associated disorders, then treatment is provided, but the treatments are inadequate in effectively targeting the underlying immune dysfunction
Solution Approach 1:
The patent changes the therapeutic parameter by using anti-BDCA2 antibodies that specifically target plasmacytoid dendritic cells, altering the mechanism of action from non-specific to BDCA2-specific targeting. This enables effective modulation of type I interferon production and immune response in BDCA2-associated disorders
Solution Approach 2:
The anti-BDCA2 antibody acts as an intermediary that binds to BDCA2 on the surface of plasmacytoid dendritic cells, blocking their activation and subsequent type I interferon production. This intermediary mechanism specifically targets the dysfunctional immune pathway without affecting other immune cells
2Reliability
If pharmaceutical compositions are formulated with specific concentrations and excipients, then therapeutic efficacy is enhanced, but formulation complexity increases
Solution Approach 1:
The patent optimizes formulation parameters including antibody concentration (10-100 mg/mL), pH (5.0-7.0), and excipient concentrations to enhance therapeutic efficacy while maintaining stability. Specific parameters like sucrose (0.1-5%), arginine hydrochloride (10-100 mM), and polysorbate-80 (0.01-0.1%) are carefully controlled
Solution Approach 2:
The pharmaceutical composition uses a composite formulation combining the anti-BDCA2 antibody with multiple excipients (sucrose, arginine hydrochloride, polysorbate-80, histidine) that work synergistically to maintain stability, prevent aggregation, and enhance therapeutic efficacy
Data Source
AI summary
Formulations and dosage regimens of anti-Blood Dendritic Cell Antigen 2 (BDCA2) antibodies are provided. These formulations and dosage regimens find use in the treatment of BDCA2-associated disorders such as systematic lupus erythematosus, cutaneous lupus erythematosus, and discoid lupus erythematosus, and cytokine release syndrome.